Nerandomilast is posed to be Boehringer Ingelheim’s successor to its blockbuster Ofev (nintedanib)in IPF and PPF.

The FDA has granted orphan drug designation (ODD) and RPDD to Arbor Biotechnologies' ABO-101, to treat primary hyperoxaluria ...

The Washington University trial comes as part of a larger platform study which hopes to understand if Alzheimer's disease can ...

The proposed guidance aims to provide a framework for the approval of personalised mRNA-based cancer vaccines.

VectorBuilder's partner, Ucello, announced that its CD19-targeting umbilical cord blood-derived allogeneic CAR-T cell therapy ...

Clinical trials of the first drugs designed with the help of artificial intelligence could commence this year, Google DeepMind CEO Demis Hassabis suggested Tuesday. Speaking on a panel at the World ...

It’s true to say that drug usage has a variety of negative consequences for its users and, on the whole, governments are right to advise against it. People in New York who smoke cannabis should ...

A non-opioid investigational drug with promising pre-clinical results in treating neuropathic pain has passed an important hurdle after the study's safety review committee (SRC) reviewed the data from ...

Some of China’s senior doctors are raising concern over the quality of domestic generic medicines that have largely replaced western brand-name drugs at hospitals, amid a rare public backlash ...

Blockbuster obesity drugs such as Ozempic have been celebrated for their ability to promote weight loss and treat a surprising range of other conditions, from heart problems to Parkinson’s disease.